<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02792673</url>
  </required_header>
  <id_info>
    <org_study_id>Assisted Reproduction Unit - 1</org_study_id>
    <nct_id>NCT02792673</nct_id>
  </id_info>
  <brief_title>Comparative Study of Three Different Embryo Transfer Media in ICSI Cycles</brief_title>
  <official_title>Comparative Study Between Three Different Embryo Transfer Media: Hyaluronan-enriched Medium &quot;Embryo Glue®&quot;, 30% Protein-supplemented Culture Medium &quot;Global Total®&quot; and Autologous Follicular Fluid Concerning &quot;Chemical and Clinical&quot; Pregnancy Rate and &quot;Ongoing Pregnancy and Miscarriage&quot; Rates in ICSI Cycles</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>South Valley University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ibn Sina Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Qena Fertility Center, Qena, Egypt</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>South Valley University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study design is a prospective randomized uncontrolled clinical trial. It will include 150
      cases.

      The aim of this study is to compare the efficacy of three different media used for embryo
      transfer regarding &quot;chemical and clinical&quot; pregnancy rate, implantation rate and ongoing
      pregnancy and miscarriage rates in IVF and ICSI cycles.

      The three different embryo transfer media are:

        1. Hyaluronan-enriched medium &quot;Embryo Glue®&quot;

        2. 30% Protein-supplemented Culture medium &quot;Global Total®&quot;

        3. Autologous Follicular Fluid (a Novel technique) In order to establish the optimal media
           for embryo transfer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Two or three embryos will be transferred at day 5 after ovum pick-up (OPU).

      The patients will be divided randomly (closed envelop method) into 3 groups:

        -  Group A (50 patients): embryos will be transferred using a medium supplemented with 0.5
           mg/mL of hyaluronic acid (EmbryoGlue®, Vitrolife, Sweden) for 20 minutes before
           intrauterine transfer took place

        -  Group B (50 patients): embryos will be transferred using a medium of 30%
           Protein-supplemented Culture Medium (Global total®, Life Global group, Canada) for 20
           minutes.

        -  Group C (50 patients): a novel technique in which embryos will be transferred using a
           medium of autologous Follicular Fluid for 20 minutes.

      Follicular fluid will be collected in a sterile procedure, centrifuged for 20 minutes in an
      embryo test tube. The supernatant will be removed in a sterilized technique then heated to
      56°C for 30 minutes then filtered through 0.22 micron filter. Gentamycin sulphate will be
      added at a concentration of 10 µg/mL then the liquid is preserved in a normal freezer.

      Defreezing follicular fluid will be performed at day-1 before embryo transfer. The follicular
      fluid will be warmed to room temperature. Preparation of embryo transfer media will be
      performed as usual, will be covered with paraffin oil (Ovoil®, Vitrolife, Sweeden) and then
      incubated overnight in 7% CO2, 9% O2, 22% N2.

      All embryo transfers will be performed using an embryo transfer catheter (Labotect catheter,
      Labotect GmbH, Germany).

      Number of embryos transferred will be according to ASRM guideline 2013 on day 5 after ovum
      pick-up (OPU).
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Chemical pregnancy rate</measure>
    <time_frame>14 days after embryo transfer</time_frame>
    <description>assessed by quantitative β hCG in the serum</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical pregnancy rate</measure>
    <time_frame>6th week of gestation</time_frame>
    <description>assessed by ultrasonic visualization of intrauterine gestational sac</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Implantation rate.</measure>
    <time_frame>6th week of gestation</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Ongoing pregnancy and miscarriage rates</measure>
    <time_frame>12th week of gestation</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Improvement of Embryo Transfer Technique</condition>
  <condition>Improvement of Implantation</condition>
  <arm_group>
    <arm_group_label>&quot;Embryo Glue®&quot;</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hyaluronan-enriched medium</description>
  </arm_group>
  <arm_group>
    <arm_group_label>&quot;Global Total®&quot;</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>30% Protein-supplemented Culture Medium</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Autologous Follicular Fluid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>a novel technique</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>embryos will be transferred using a medium of 0.5 mg/mL of Hyaluronan-enriched medium (EmbryoGlue®, Vitrolife, Sweden)</intervention_name>
    <arm_group_label>&quot;Embryo Glue®&quot;</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>embryos will be transferred using a medium of 30% Protein-supplemented Culture Medium (Global total®, Life Global group, Canada)</intervention_name>
    <arm_group_label>&quot;Global Total®&quot;</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>a novel technique in which embryos will be transferred using a medium of autologous Follicular Fluid</intervention_name>
    <arm_group_label>Autologous Follicular Fluid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Labotect embryo transfer catheter</intervention_name>
    <arm_group_label>&quot;Embryo Glue®&quot;</arm_group_label>
    <arm_group_label>&quot;Global Total®&quot;</arm_group_label>
    <arm_group_label>Autologous Follicular Fluid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age: 18-35 years

          2. Body mass index (BMI): ≤ 30

          3. Anti-mullerian hormone (AMH): 1.1 - 3

          4. No gynecological problem e.g. fibroid, endometriosis, uterine polyp, hydrosalpinx or
             adenomysis

          5. Male factor: mild to moderate oligo or asthenospermia

        Exclusion Criteria:

          1. Age: &lt;18 years or &gt;35 years

          2. Body mass index (BMI): &gt;30

          3. Anti-mullerian hormone (AMH): &lt;1.1 or &gt;3

          4. gynecological problem e.g. fibroid, endometriosis, uterine polyp, hydrosalpinx or
             adenomysis will be excluded

          5. Male factor: Abnormal sperm morphology; (globozoospermia and pin-point sperm) and
             azoospermia; (whether obstructive or non-obstructive) will be excluded

          6. Patients with recurrent implantation failure
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 23, 2016</study_first_submitted>
  <study_first_submitted_qc>June 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2016</study_first_posted>
  <last_update_submitted>June 6, 2016</last_update_submitted>
  <last_update_submitted_qc>June 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>South Valley University</investigator_affiliation>
    <investigator_full_name>Ahmed Mowafy</investigator_full_name>
    <investigator_title>Investigator</investigator_title>
  </responsible_party>
  <keyword>Embryo transfer media</keyword>
  <keyword>improvement of embryo transfer technique</keyword>
  <keyword>improvement of implantation</keyword>
  <keyword>Hyaluronan-enriched media &quot;Embryo Glue®&quot;</keyword>
  <keyword>30% Protein-supplemented Culture Medium &quot;Global Total®&quot;</keyword>
  <keyword>Autologous Follicular Fluid as embryo transfer medium</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

